Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoxHIV study
2025-521153-16-00Phase 3Authorised
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxycycline in sexually transmitted disease (STD), gonorrhea, Chlamydia trachomatis infection and 1 more (2 arms), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: Incidence rate ratio of symptomatic Neisseria gonorrhoeae, Chlamydia trachomatis, and all Treponema pallidum infections. Planned start Jun 2025; status: authorised.
02
Drugs
doxycycline
03
Conditions
sexually transmitted disease (STD)gonorrheaChlamydia trachomatis infectionsyphilis
Beyond the preview
Go deeper on 2025-521153-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521153-16-00.